DR NILESH KATE
MBBS,MD
ASSOCIATE PROF
DEPT. OF PHYSIOLOGY
HAEMOSTASIS II
ANTIHAEMOSTATIC
MECHANISMS
OBJECTIVES.
 Anti-haemostatic
mechanism.
 Bleeding disorders.
 Laboratory tests
Monday, June 20, 2016
ANTIHAEMOSTATIC MECHANISM
 The factors which balance the tendency of blood to
clot in VIVO forms Anti-Haemostatic Factors.
 Factors preventing platelet aggregation
 Factors preventing coagulation
 Factors causing fibrinolysis.
Monday, June 20, 2016
FACTORS PREVENTING
PLATELET AGGREGATION
 PROSTACYCLIN – Endogenous
factor inhibit Thromboxane
A2( Promote Platelet
Aggregation).
 Normally balance between
Prostacyclin
Thromboxane A2
Prevents Intravascular spread of
plug.
Monday, June 20, 2016
FACTORS PREVENTING
COAGULATION
 Circulating Anticoagulant
 Heparin
 Anti-thrombin III or heparin Co-factor II
 Protein C.
Monday, June 20, 2016
HEPARIN
 Powerful Natural Anti-
coagulant.
 First isolated from Liver.
 Its Polysaccharides
containing sulphate groups
 Mol wt – 15000-18000
dalton.
 Secreted by Basophils &
mast cells.
 Destroyed by Heparinase.
Monday, June 20, 2016
HEPARIN
MECHANISM OF ACTION
 Prevents activation of
Prothrombin to
Thrombin.
 Inhibits action of
thrombin on fibrinogen.
 Facilitate action of
Antithrombin –III &
inhibits factor IX,X,XII &
XII
Monday, June 20, 2016
ANTI-THROMBIN III OR
HEPARIN CO-FACTOR II
 Present in plasma &
vascular endothelium.
 Inactivates
Coagulation factors
including thrombin.
Monday, June 20, 2016
PROTEIN C.
 Plasma protein from
liver.
 Along with
Thrombomodulin &
protein S forms
Negative feedback for
Coagulatory process
under control.
Monday, June 20, 2016
PROTEIN C PATHWAY INHIBITING
COAGULATION & PROMOTING
FIBRINOLYSIN.
Monday, June 20, 2016
THROMBOMODULIN
 Thrombin binding
protein produced by
endothelial cells
except cerebral
microcirculation.
 Converts thrombin
into protein C
activator.
Monday, June 20, 2016
FIBRINOLYTIC MECHANISM
 FIBRINOLYSIS –
dissolution of Fibrin.
 Important component
is Plasmin or
fibrinolysin present in
inactive form called
plasminogen or
Profibrinolysin.
Monday, June 20, 2016
FACTORS CAUSING FIBRINOLYSIS
 Plasminogen
 plasmin.
 Extrinsic plasminogen
activator system
 Intrinsic plasminogen
activator system
Monday, June 20, 2016
PLASMINOGEN
 Beta globulin
produced by liver.
 It is associated with
fibrinogen molecule.
 Plasminogen is
activated by
plasminogen activator
system to produce
PLASMIN.
Monday, June 20, 2016
PLASMIN.
 Powerful protease formed
from plasminogen.
 Lysis fibrin & fibrinogen into
fragments known as fibrin
degradation products that
inhibit thrombin.
 2 plasminogen activator
system.
 Extrinsic
 Intrinsic
Monday, June 20, 2016
EXTRINSIC PLASMINOGEN
ACTIVATOR SYSTEM
 Predominant
mechanism
 In its absence
extensive fibrin
deposition occurs.
 Its absence causes
 delayed wound healing
 Defect in growth &
fertility.
Monday, June 20, 2016
FIBRINOLYTIC MECHANISM OPERATING
THROUGH EXTRINSIC PLASMINOGEN
ACTIVATOR SYSTEM.
PLASMINOGEN
TPA
THROMBIN
UPA
PLASMIN
Fibrin Fibrin degradation
product (FDP)
Monday, June 20, 2016
TISSUE PLASMINOGEN
ACTIVATOR
 Also called Vascular Plasminogen Activator
released from vascular endothelium.
 Its release depend upon release of Serotonin from
platelets & release of adrenaline.
 E.g – In soldier in battlefield there is massive
fibrinolysis due to release of adrenaline.
 TPA is now produced by Recombinant DNA
technology & used clinically.
Monday, June 20, 2016
UROKINASE TYPE
PLASMINOGEN ACTIVATOR
 Found in endothelial cells, renal cells &
Tumor cells.
 E.g. – STREPTOKINASE &
STAPHYLOKINASE are bacterial enzymes
causes activation of Plasmin like TPA & UPA.
Monday, June 20, 2016
INTRINSIC PLASMINOGEN
ACTIVATOR SYSTEM
 Contact factor XIIa & Kallikrein intiate
clotting mechanism also stimulate
dissolution of clot by activating plasminogen
& form intrinsic plasminogen activator
system.
Monday, June 20, 2016
FIBRINOLYTIC MECHANISM OPERATING
THROUGH INTRINSIC PLASMINOGEN
ACTIVATOR SYSTEM.
Prekallikrein
 XII XIIa
Kallikrein
Thrombin
Plasminogen Plasmin
Fibrin Fibrin Degradation
Product (FDP)
Monday, June 20, 2016
FIBRINOLYSIS INHIBITORS
 Rate of fibrinolysis is influenced by
promoters & inhibitors.
 Various INHIBITOR s are
 ANTIPLASMIN – alpha2 antiplasmin
 Drugs – aprotinin & Epsilon amino caproic acid
(EACA)
 Inhibitors are present in plasma, blood cells,
tissues & extracellular matrix.
Monday, June 20, 2016
PHYSIOLOGICAL ROLE OF
FIBRINOLYSIS SYSTEM
 Cleaning the minute clots of tiny vessels
 Promote normal healing process.
 Liquefaction of menstural clot.
 Liquefaction of sperms in the epididymis.
 Role in inflammatory response
Monday, June 20, 2016
ANTICOAGULANTS
 Substances which delay or prevent process of
coagulation of blood.
 In vitro – done by substances which sequester
calcium – sodium citrate or oxalate, sodium
edetate(EDTA)
 In vivo –done by
 Antagonizing clotting factors – heparin
 Destruction of fibrinogen
 By inhibiting synthesis of factors – II,VII,IX & X
Monday, June 20, 2016
ANTICOAGULANTS
 Endogenous Anticoagulants – inside body
naturally – Heparin, antithrombin III & protein
C
 Exogenous anticoagulants or decalcifying
agents.
 Heparin
 Calcium sequesters
 Vitamin K antagonists
 Defibrination substances.
Monday, June 20, 2016
CALCIUM SEQUESTERS
 By removing Ca from the blood.
 Two types of agent
 One which form insoluble salts with Ca – Na citrate
& Na oxalate
 Calcium Chelators – which binds with Ca – EDTA.
Monday, June 20, 2016
VITAMIN K ANTAGONISTS
 Used orally.
 MOA – occupy Vit K active site & prevent Vit K to
function – inhibit synthesis of Vit K dependent
factors as VII,IX & X
 Eg- Coumarin derivatives
 Warfarin
 Phenindione
 Nicoumalone
Monday, June 20, 2016
DEFIBRINATION SUBSTANCES.
 Which causes destruction of fibrinogen.
 Malaysian pit viper venom
 Arvin or ancord – preparation of snake
venom.
Monday, June 20, 2016
BLEEDING DISORDERS
 Spontaneous escape of blood from blood
vessels or
 Persistent or excessive bleeding following
minor injuries like tooth extraction etc.
Monday, June 20, 2016
BLEEDING DISORDERS
 Classification of bleeding disorders.
 Platelet disorders
 Deficiency of platelets
 Functional disorders of platelets
 Coagulation disorders or defective
coagulation mechanisms
 Deficiency of clotting factors
 Vit K deficiency.
 Anticoagulant overdose.
 DIC
Monday, June 20, 2016
BLEEDING DISORDERS
 Classification of bleeding disorders.
 Vascular disorders. Damage of capillary
endothelium(Non-thrombocytopenic
Purpura)
 Infection by bacteria & toxins,Toxic effects of
drugs & chemicals
 Avitaminosis , alergic purpura, connective
tissue diseases.
Monday, June 20, 2016
PURPURA
 Group of bleeding
disorders due to
various causes.
 PURPURA – purple
coloured petechial
hemorrhages &
bruises in the skin.
Monday, June 20, 2016
CAUSES AND TYPES OF
PURPURA
 Platelet disorders.
 Deficiency of platelets. (thrombocytopenic Purpura)
 Normal count – 1.5 l- 4 lac/mm3
 Below 1.5lac – thrombocytopenia
 Causes –
 Primary – cause not known
 Secondary –
 Bone marrow depression.
 Leukemia.
 Acute septicemia, toxemia & uremia
 Hypersplenism.
Monday, June 20, 2016
CAUSES AND TYPES OF
PURPURA
 Functional disorders of platelets.
(Thrombosthenic purpura)
 Drug induced defects –aspirin
 Von-willebrand’s disease.
 Vascular disorders (Non-
thrombocytopenic Purpura)
Monday, June 20, 2016
CAUSES OF NON-
THROMBOCYTOPENIC PURPURA.
 Drug induced damage to capillary wall.
 Deficiency of vitamin-C
 Allergic purpura.
 Infections
 Senile purpura
 Connective tissue diseases.
Monday, June 20, 2016
HAEMOPHILIA
 Group of disorders
due to hereditary
deficiency of
coagulation.
 Characterized by
Bleeding tendencies
with Increased
clotting time.
Monday, June 20, 2016
HAEMOPHILIA
 Haemophilia-A
 Haemophilia-B
 Haemophilia-C
Monday, June 20, 2016
HAEMOPHILIA-A
 Classical haemophilia
due to Deficiency of
factor VIII.
 Sex linked recessive
disease affects males
and females carrier.
 Clinical features not
apparent since birth but
start early in life.
Monday, June 20, 2016
HAEMOPHILIA-A
 c/f – tendency to bleed into soft tissues, muscle, joints , GI
tracts, urinary tracts & from nose
 Severely damaged joints.
 Hemorrhage into soft tissue of mouth cause respiratory
obstruction & death by suffocation.
 Normal bleeding time, platelet count & PT but prolonged CT
& PTT.
 T/t – repeated small fresh blood, fresh plasma, factor VIII
conc.
Monday, June 20, 2016
HAEMOPHILIA-B
 Known as Christmas
Disease due to
Deficiency of factor IX.
 Reccessive X-Linked
disease occurs in males,
transmitted by females.
 T/t – Fresh blood
transfusion.
Monday, June 20, 2016
HAEMOPHILIA-C
 Deficiency of
PTA(Factor X)
 Inherited as Mendelian
dominant affects both
males & females.
 Without bleeding
tendencies.
 CT may be prolonged or
normal.
Monday, June 20, 2016
DISSEMINATED INTRAVASCULAR
COAGULATION.
 Condition when clotting
mechanism is activated
in widespread
circulation.
 Due to wide spread
coagulation plugging of
small vessels leads to
decreased O2 &
nutrient supply- organ
damage.
Monday, June 20, 2016
DISSEMINATED INTRAVASCULAR
COAGULATION.
 Most of the coagulation
factors & platelets used up
leads to its deficiency
causing bleeding tendencies.
So called consumption
coagulopathy.
 Fibrin degradation product
formed due to fibrinolysis of
clot have anti-haemostatic
effect further aggravate
bleeding tendency.
Monday, June 20, 2016
LABORATORY TESTS IN
BLEEDING DISORDERS
 Bleeding time(BT)
 Definition – time interval between
skin prick and the arrest of bleeding.
 Procedure.
 Duke’s method – take a prick at finger
skin , blood is wiped at 15 sec interval till
it stops
 Normal time :- 1-6 min.
 Ivy’s method – apply 40 mm Hg at upper
arm with BP cuff & take deep prick on ant
surface of skin of forearm
 Normal time – 3-6min.
Monday, June 20, 2016
LABORATORY TESTS IN
BLEEDING DISORDERS
 Prolonged BT – occurs in purpura & normal in Haemophilia.
 Capillary fragility tests of Hess or Tourniquet test – To
assess the mechanical fragility of capillary by raising
pressure.
 Procedure – A circle of 1 inch diameter is marked on forearm
& pressure midway between systolic & diastolic is applied on
upper arm for 15min using cuff. any purple spot is marked
with blue ink.
Monday, June 20, 2016
PLATELET COUNT
 Normal Platelet Count – 1.5 – 4 lac/mm3
 Procedure
 Direct method – using Reese-E-Kar fluid counted in
Haemocytometer.
 Indirect method – from RBC count & RBC:platelet
ratio. 1platelet :16-18 RBC.
Monday, June 20, 2016
COAGULATION TIME.
 Def – Time taken by the fresh
blood to get coagulated by
formation of fibrin threads.
 Procedure.
 Capillary tube method – 3-6 min
 Modified Lee & white test tube
method (whole blood coagulation
time) – blood is collected by
venepuncture & kept in a test tube &
time is noted to form a clot.
 Normal time – 8-12 min.
Monday, June 20, 2016
IMPORTANCE OF CLOTTING
TIME
 Physiologically – CT prolonged during
mensturation & before & during Parturition.
 Pathologically – Prolonged in
 Haemophilia,
 liver diseases,
 Afibrinogenemia,
 Christmas disease,
 vit K deficiency
 DIC
Monday, June 20, 2016
PROTHROMBIN TIME
 Procedure – Quick’s one stage
method
 Oxalated or citrated plasma of
patient are added to tissue
thromboplastin & Ca chloride
solution & mixture incubated at
37o
c – result is conversion of fluid
plasma to gel.
 NT – 11-16 sec
 Importance – used to monitor
pt receiving anticoagulant
therapy.
 Increase in
 Pts on oral
anticoagulants, liver
failure, vit K deficiency,
deficiency of factor
II,V,VII,X
 Normal in
 Haemophilia &
Christmas disease
Monday, June 20, 2016
PARTIAL THROMBOPLASTIN
TIME
 Procedure – To oxalated & citrated plasma
of patients kaolin & ca chloride are added &
mixture is incubated at 370
C,
 Result is formation of plasma gel
 Importance – used to monitor Heparin
therapy
 Prolonged in – haemophilia, Von-willebrand
disease, liver failure, deficiency of XII,
anticoagulant therapy & intravascular clotting.
Monday, June 20, 2016
THROMBOPLASTIN
GENERATION TESTS.
 Normal value – 12 sec or less
 Prolonged Value Indicates – Deficiency of
factors needed to form prothrombin
activator by intrinsic mechanism i.e factor V,
VIII,IX & X
 In Haemophilia – PT is normal but TGT
prolonged.
Monday, June 20, 2016
THROMBIN TIME
 Measures final step in coagulation i.e
functional fibrinogen available.
 Thrombin is added to plasma which covert
fibrinogen to fibrin
 End Point – Formation of clot
 NT – 10 sec
 Prolonged in Hyperfibrinogenemia,
dysfibrinogenemia, DIC & heparin treatment.
Monday, June 20, 2016
CLOT RETRACTION TEST.
 It measures time needed for contraction of
clot.
 Indicate function & number of platelets
 NT – 2-24 hrs.
 Increased in – thrombocytopenia.
 Clot is soft & small in – Thrombosthenia
( Functional disorder of platelet)
Monday, June 20, 2016
Thank
You

Haemostasis ii

  • 1.
    DR NILESH KATE MBBS,MD ASSOCIATEPROF DEPT. OF PHYSIOLOGY HAEMOSTASIS II ANTIHAEMOSTATIC MECHANISMS
  • 2.
    OBJECTIVES.  Anti-haemostatic mechanism.  Bleedingdisorders.  Laboratory tests Monday, June 20, 2016
  • 3.
    ANTIHAEMOSTATIC MECHANISM  Thefactors which balance the tendency of blood to clot in VIVO forms Anti-Haemostatic Factors.  Factors preventing platelet aggregation  Factors preventing coagulation  Factors causing fibrinolysis. Monday, June 20, 2016
  • 4.
    FACTORS PREVENTING PLATELET AGGREGATION PROSTACYCLIN – Endogenous factor inhibit Thromboxane A2( Promote Platelet Aggregation).  Normally balance between Prostacyclin Thromboxane A2 Prevents Intravascular spread of plug. Monday, June 20, 2016
  • 5.
    FACTORS PREVENTING COAGULATION  CirculatingAnticoagulant  Heparin  Anti-thrombin III or heparin Co-factor II  Protein C. Monday, June 20, 2016
  • 6.
    HEPARIN  Powerful NaturalAnti- coagulant.  First isolated from Liver.  Its Polysaccharides containing sulphate groups  Mol wt – 15000-18000 dalton.  Secreted by Basophils & mast cells.  Destroyed by Heparinase. Monday, June 20, 2016
  • 7.
    HEPARIN MECHANISM OF ACTION Prevents activation of Prothrombin to Thrombin.  Inhibits action of thrombin on fibrinogen.  Facilitate action of Antithrombin –III & inhibits factor IX,X,XII & XII Monday, June 20, 2016
  • 8.
    ANTI-THROMBIN III OR HEPARINCO-FACTOR II  Present in plasma & vascular endothelium.  Inactivates Coagulation factors including thrombin. Monday, June 20, 2016
  • 9.
    PROTEIN C.  Plasmaprotein from liver.  Along with Thrombomodulin & protein S forms Negative feedback for Coagulatory process under control. Monday, June 20, 2016
  • 10.
    PROTEIN C PATHWAYINHIBITING COAGULATION & PROMOTING FIBRINOLYSIN. Monday, June 20, 2016
  • 11.
    THROMBOMODULIN  Thrombin binding proteinproduced by endothelial cells except cerebral microcirculation.  Converts thrombin into protein C activator. Monday, June 20, 2016
  • 12.
    FIBRINOLYTIC MECHANISM  FIBRINOLYSIS– dissolution of Fibrin.  Important component is Plasmin or fibrinolysin present in inactive form called plasminogen or Profibrinolysin. Monday, June 20, 2016
  • 13.
    FACTORS CAUSING FIBRINOLYSIS Plasminogen  plasmin.  Extrinsic plasminogen activator system  Intrinsic plasminogen activator system Monday, June 20, 2016
  • 14.
    PLASMINOGEN  Beta globulin producedby liver.  It is associated with fibrinogen molecule.  Plasminogen is activated by plasminogen activator system to produce PLASMIN. Monday, June 20, 2016
  • 15.
    PLASMIN.  Powerful proteaseformed from plasminogen.  Lysis fibrin & fibrinogen into fragments known as fibrin degradation products that inhibit thrombin.  2 plasminogen activator system.  Extrinsic  Intrinsic Monday, June 20, 2016
  • 16.
    EXTRINSIC PLASMINOGEN ACTIVATOR SYSTEM Predominant mechanism  In its absence extensive fibrin deposition occurs.  Its absence causes  delayed wound healing  Defect in growth & fertility. Monday, June 20, 2016
  • 17.
    FIBRINOLYTIC MECHANISM OPERATING THROUGHEXTRINSIC PLASMINOGEN ACTIVATOR SYSTEM. PLASMINOGEN TPA THROMBIN UPA PLASMIN Fibrin Fibrin degradation product (FDP) Monday, June 20, 2016
  • 18.
    TISSUE PLASMINOGEN ACTIVATOR  Alsocalled Vascular Plasminogen Activator released from vascular endothelium.  Its release depend upon release of Serotonin from platelets & release of adrenaline.  E.g – In soldier in battlefield there is massive fibrinolysis due to release of adrenaline.  TPA is now produced by Recombinant DNA technology & used clinically. Monday, June 20, 2016
  • 19.
    UROKINASE TYPE PLASMINOGEN ACTIVATOR Found in endothelial cells, renal cells & Tumor cells.  E.g. – STREPTOKINASE & STAPHYLOKINASE are bacterial enzymes causes activation of Plasmin like TPA & UPA. Monday, June 20, 2016
  • 20.
    INTRINSIC PLASMINOGEN ACTIVATOR SYSTEM Contact factor XIIa & Kallikrein intiate clotting mechanism also stimulate dissolution of clot by activating plasminogen & form intrinsic plasminogen activator system. Monday, June 20, 2016
  • 21.
    FIBRINOLYTIC MECHANISM OPERATING THROUGHINTRINSIC PLASMINOGEN ACTIVATOR SYSTEM. Prekallikrein  XII XIIa Kallikrein Thrombin Plasminogen Plasmin Fibrin Fibrin Degradation Product (FDP) Monday, June 20, 2016
  • 22.
    FIBRINOLYSIS INHIBITORS  Rateof fibrinolysis is influenced by promoters & inhibitors.  Various INHIBITOR s are  ANTIPLASMIN – alpha2 antiplasmin  Drugs – aprotinin & Epsilon amino caproic acid (EACA)  Inhibitors are present in plasma, blood cells, tissues & extracellular matrix. Monday, June 20, 2016
  • 23.
    PHYSIOLOGICAL ROLE OF FIBRINOLYSISSYSTEM  Cleaning the minute clots of tiny vessels  Promote normal healing process.  Liquefaction of menstural clot.  Liquefaction of sperms in the epididymis.  Role in inflammatory response Monday, June 20, 2016
  • 24.
    ANTICOAGULANTS  Substances whichdelay or prevent process of coagulation of blood.  In vitro – done by substances which sequester calcium – sodium citrate or oxalate, sodium edetate(EDTA)  In vivo –done by  Antagonizing clotting factors – heparin  Destruction of fibrinogen  By inhibiting synthesis of factors – II,VII,IX & X Monday, June 20, 2016
  • 25.
    ANTICOAGULANTS  Endogenous Anticoagulants– inside body naturally – Heparin, antithrombin III & protein C  Exogenous anticoagulants or decalcifying agents.  Heparin  Calcium sequesters  Vitamin K antagonists  Defibrination substances. Monday, June 20, 2016
  • 26.
    CALCIUM SEQUESTERS  Byremoving Ca from the blood.  Two types of agent  One which form insoluble salts with Ca – Na citrate & Na oxalate  Calcium Chelators – which binds with Ca – EDTA. Monday, June 20, 2016
  • 27.
    VITAMIN K ANTAGONISTS Used orally.  MOA – occupy Vit K active site & prevent Vit K to function – inhibit synthesis of Vit K dependent factors as VII,IX & X  Eg- Coumarin derivatives  Warfarin  Phenindione  Nicoumalone Monday, June 20, 2016
  • 28.
    DEFIBRINATION SUBSTANCES.  Whichcauses destruction of fibrinogen.  Malaysian pit viper venom  Arvin or ancord – preparation of snake venom. Monday, June 20, 2016
  • 29.
    BLEEDING DISORDERS  Spontaneousescape of blood from blood vessels or  Persistent or excessive bleeding following minor injuries like tooth extraction etc. Monday, June 20, 2016
  • 30.
    BLEEDING DISORDERS  Classificationof bleeding disorders.  Platelet disorders  Deficiency of platelets  Functional disorders of platelets  Coagulation disorders or defective coagulation mechanisms  Deficiency of clotting factors  Vit K deficiency.  Anticoagulant overdose.  DIC Monday, June 20, 2016
  • 31.
    BLEEDING DISORDERS  Classificationof bleeding disorders.  Vascular disorders. Damage of capillary endothelium(Non-thrombocytopenic Purpura)  Infection by bacteria & toxins,Toxic effects of drugs & chemicals  Avitaminosis , alergic purpura, connective tissue diseases. Monday, June 20, 2016
  • 32.
    PURPURA  Group ofbleeding disorders due to various causes.  PURPURA – purple coloured petechial hemorrhages & bruises in the skin. Monday, June 20, 2016
  • 33.
    CAUSES AND TYPESOF PURPURA  Platelet disorders.  Deficiency of platelets. (thrombocytopenic Purpura)  Normal count – 1.5 l- 4 lac/mm3  Below 1.5lac – thrombocytopenia  Causes –  Primary – cause not known  Secondary –  Bone marrow depression.  Leukemia.  Acute septicemia, toxemia & uremia  Hypersplenism. Monday, June 20, 2016
  • 34.
    CAUSES AND TYPESOF PURPURA  Functional disorders of platelets. (Thrombosthenic purpura)  Drug induced defects –aspirin  Von-willebrand’s disease.  Vascular disorders (Non- thrombocytopenic Purpura) Monday, June 20, 2016
  • 35.
    CAUSES OF NON- THROMBOCYTOPENICPURPURA.  Drug induced damage to capillary wall.  Deficiency of vitamin-C  Allergic purpura.  Infections  Senile purpura  Connective tissue diseases. Monday, June 20, 2016
  • 36.
    HAEMOPHILIA  Group ofdisorders due to hereditary deficiency of coagulation.  Characterized by Bleeding tendencies with Increased clotting time. Monday, June 20, 2016
  • 37.
    HAEMOPHILIA  Haemophilia-A  Haemophilia-B Haemophilia-C Monday, June 20, 2016
  • 38.
    HAEMOPHILIA-A  Classical haemophilia dueto Deficiency of factor VIII.  Sex linked recessive disease affects males and females carrier.  Clinical features not apparent since birth but start early in life. Monday, June 20, 2016
  • 39.
    HAEMOPHILIA-A  c/f –tendency to bleed into soft tissues, muscle, joints , GI tracts, urinary tracts & from nose  Severely damaged joints.  Hemorrhage into soft tissue of mouth cause respiratory obstruction & death by suffocation.  Normal bleeding time, platelet count & PT but prolonged CT & PTT.  T/t – repeated small fresh blood, fresh plasma, factor VIII conc. Monday, June 20, 2016
  • 40.
    HAEMOPHILIA-B  Known asChristmas Disease due to Deficiency of factor IX.  Reccessive X-Linked disease occurs in males, transmitted by females.  T/t – Fresh blood transfusion. Monday, June 20, 2016
  • 41.
    HAEMOPHILIA-C  Deficiency of PTA(FactorX)  Inherited as Mendelian dominant affects both males & females.  Without bleeding tendencies.  CT may be prolonged or normal. Monday, June 20, 2016
  • 42.
    DISSEMINATED INTRAVASCULAR COAGULATION.  Conditionwhen clotting mechanism is activated in widespread circulation.  Due to wide spread coagulation plugging of small vessels leads to decreased O2 & nutrient supply- organ damage. Monday, June 20, 2016
  • 43.
    DISSEMINATED INTRAVASCULAR COAGULATION.  Mostof the coagulation factors & platelets used up leads to its deficiency causing bleeding tendencies. So called consumption coagulopathy.  Fibrin degradation product formed due to fibrinolysis of clot have anti-haemostatic effect further aggravate bleeding tendency. Monday, June 20, 2016
  • 44.
    LABORATORY TESTS IN BLEEDINGDISORDERS  Bleeding time(BT)  Definition – time interval between skin prick and the arrest of bleeding.  Procedure.  Duke’s method – take a prick at finger skin , blood is wiped at 15 sec interval till it stops  Normal time :- 1-6 min.  Ivy’s method – apply 40 mm Hg at upper arm with BP cuff & take deep prick on ant surface of skin of forearm  Normal time – 3-6min. Monday, June 20, 2016
  • 45.
    LABORATORY TESTS IN BLEEDINGDISORDERS  Prolonged BT – occurs in purpura & normal in Haemophilia.  Capillary fragility tests of Hess or Tourniquet test – To assess the mechanical fragility of capillary by raising pressure.  Procedure – A circle of 1 inch diameter is marked on forearm & pressure midway between systolic & diastolic is applied on upper arm for 15min using cuff. any purple spot is marked with blue ink. Monday, June 20, 2016
  • 46.
    PLATELET COUNT  NormalPlatelet Count – 1.5 – 4 lac/mm3  Procedure  Direct method – using Reese-E-Kar fluid counted in Haemocytometer.  Indirect method – from RBC count & RBC:platelet ratio. 1platelet :16-18 RBC. Monday, June 20, 2016
  • 47.
    COAGULATION TIME.  Def– Time taken by the fresh blood to get coagulated by formation of fibrin threads.  Procedure.  Capillary tube method – 3-6 min  Modified Lee & white test tube method (whole blood coagulation time) – blood is collected by venepuncture & kept in a test tube & time is noted to form a clot.  Normal time – 8-12 min. Monday, June 20, 2016
  • 48.
    IMPORTANCE OF CLOTTING TIME Physiologically – CT prolonged during mensturation & before & during Parturition.  Pathologically – Prolonged in  Haemophilia,  liver diseases,  Afibrinogenemia,  Christmas disease,  vit K deficiency  DIC Monday, June 20, 2016
  • 49.
    PROTHROMBIN TIME  Procedure– Quick’s one stage method  Oxalated or citrated plasma of patient are added to tissue thromboplastin & Ca chloride solution & mixture incubated at 37o c – result is conversion of fluid plasma to gel.  NT – 11-16 sec  Importance – used to monitor pt receiving anticoagulant therapy.  Increase in  Pts on oral anticoagulants, liver failure, vit K deficiency, deficiency of factor II,V,VII,X  Normal in  Haemophilia & Christmas disease Monday, June 20, 2016
  • 50.
    PARTIAL THROMBOPLASTIN TIME  Procedure– To oxalated & citrated plasma of patients kaolin & ca chloride are added & mixture is incubated at 370 C,  Result is formation of plasma gel  Importance – used to monitor Heparin therapy  Prolonged in – haemophilia, Von-willebrand disease, liver failure, deficiency of XII, anticoagulant therapy & intravascular clotting. Monday, June 20, 2016
  • 51.
    THROMBOPLASTIN GENERATION TESTS.  Normalvalue – 12 sec or less  Prolonged Value Indicates – Deficiency of factors needed to form prothrombin activator by intrinsic mechanism i.e factor V, VIII,IX & X  In Haemophilia – PT is normal but TGT prolonged. Monday, June 20, 2016
  • 52.
    THROMBIN TIME  Measuresfinal step in coagulation i.e functional fibrinogen available.  Thrombin is added to plasma which covert fibrinogen to fibrin  End Point – Formation of clot  NT – 10 sec  Prolonged in Hyperfibrinogenemia, dysfibrinogenemia, DIC & heparin treatment. Monday, June 20, 2016
  • 53.
    CLOT RETRACTION TEST. It measures time needed for contraction of clot.  Indicate function & number of platelets  NT – 2-24 hrs.  Increased in – thrombocytopenia.  Clot is soft & small in – Thrombosthenia ( Functional disorder of platelet) Monday, June 20, 2016
  • 54.